You are here

DOJ and DEA Propose Lowering Opioid Production Quotas by 10% in 2019

Pressure to Rein in Production Persists

The Department of Justice (DOJ) and U.S. Drug Enforcement Administration (DEA) have proposed to reduce manufacturing quotas for six of the most frequently abused opioids by 10%, on average, in 2019.

The DEA has proposed to scale back on the production of commonly prescribed schedule II opioids including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, and fentanyl. Since 2016, production quotas for these drugs have dropped by an average of 44%. The proposal will be included in the agencies’ final rule that aims to change their regulations and quota processes to more effectively limit opioid diversion, which will be reviewed by the state attorneys general.

Although the DEA reduced its production quotas of opioids by at least 25% in 2016, DEA-approved production volumes still remain high; oxycodone levels in 2017 were 55% higher than in 2007.

Source: Modern Healthcare, August 20, 2018

Recent Headlines

‘The Perfect Drug for Trauma-Focused Psychotherapy’
Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients